Investing.com - Nabriva Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Nabriva Therapeutics announced earnings per share of $-0.21 on revenue of $8.9M. Analysts polled by Investing.com anticipated EPS of $-0.22 on revenue of $8.9M.
Nabriva Therapeutics shares are down 45.45% from the beginning of the year and are trading at $1.3200 , down-from-52-week-high.They are under-performing the Nasdaq which is up 23.26% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on Tuesday, October 19, 2021, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Pfizer had beat expectations on Tuesday, November 2, 2021 with third quarter EPS of $1.34 on revenue of $24.09B, compared to forecast for EPS of $1.08 on revenue of $22.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar